KA
TOVX icon

Kovack Advisors’s Theriva Biologics TOVX Stock Holding History

Kovack Advisors’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-4
Closed -$8K – 508
2018
Q2 		$8K Hold
4
– – ﹤0.01% 410
2018
Q1 		$11K Hold
4
– – ﹤0.01% 483
2017
Q4 		$17K Buy
4
+2
+100% +$12.5K ﹤0.01% 450
2017
Q3 		$19K Buy
+2
New +$11.6K 0.01% 338

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Kovack Advisors's TOVX Position: Q3 2018 in Review

Kovack Advisors sold out of Theriva Biologics (TOVX) in Q3 2018, closing a stake of 4 shares — an estimated $8K sold.

Kovack Advisors first reported a position in TOVX in Q3 2017 and held it in 4 quarters. The position peaked at $19K in Q3 2017. 22 funds tracked by Wall St. Rank hold TOVX as of Q3 2018.

  • Kovack Advisors reported no remaining Theriva Biologics position as of Q3 2018 after selling out during the quarter.
  • Kovack Advisors sold 4 Theriva Biologics shares in Q3 2018, an estimated $8K.
  • Kovack Advisors first reported a position in Theriva Biologics in Q3 2017 and held it in 4 quarters.
  • Kovack Advisors's Theriva Biologics position peaked at $19K in Q3 2017.
  • 22 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2018.

Based on Kovack Advisors's 13F filing for Q3 2018, filed 9 Oct 2018.